

## HUMAN CB1 FULL LENGTH PROTEIN

**Cat.#:** 12227

**Product Name:** Human CB1 Full Length Protein

**Size:** 10 µg, 50 µg and 100 µg

**Synonyms:** CANN6; CB-R; CNR1; CB1A; CB1K5; CB1R; CNR

**Target:** CB1

**UNIPROT ID:** P21554

**Description:** Human CB1 full length protein membrane nanoparticles (MNP)

**Background:** The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene.

**Species/Host:** HEK293

**Molecular Weight:** The human full length CB1 Protein has a MW of 52.7 kDa

**Formulation & Reconstitution:** Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.

**Storage & Shipping:** Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.







Figure1. Elisa plates were pre-coated with 0.5 µg/per well purified human CB1 full length membrane nanoparticles. Serial diluted anti-CB1 monoclonal antibody (28488) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CB1 monoclonal antibody binding with CB1 full length membrane nanoparticles is 439.6ng/ml.



A



C



D

Figure2. FACS analysis of CB1 MNPs A. Negative Control 1: CB1 full length membrane nanoparticles samples were stained only with Goat anti-human IgG 488 secondary antibody. B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CB1 antibody (28057) at 2µg/ml, followed by Goat anti-human IgG 488 secondary antibody. C. Negative Control 3: CB1 full length membrane nanoparticles samples were stained with anti-CCR8 antibody (an irrelevant antibody) at 2µg/ml, followed by Goat anti-human IgG 488 secondary antibody. D. CB1 full length membrane nanoparticles samples were stained with anti-CB1 antibody (28057) at 2µg/ml, followed by Goat anti-human IgG 488 secondary antibody.

